FGF23 is a key factor in the pathogenesis of chronic kidney disease–metabolic bone disease, where significant increases in plasma FGF23 concentrations occur in humans, cats and dogs in parallel with the stages of kidney disease [9,10,11]. This evidence concerns the gene FGF23 and kidney disorder.